Is Stevens Johnson Syndrome hereditary?

Stevens-Johnson Syndrome (SJS) is not considered a hereditary or strictly genetic disease, but rather an idiosyncratic, immune-mediated reaction that is heavily influenced by a person's individual genetic makeup.

While SJS is not passed directly from parent to child through a standard inheritance pattern like autosomal dominant or recessive genes, it is not purely environmental either. Instead, it is classified as a multifactorial condition. This means that an individual may have a specific genetic predisposition—often involving variations in the Human Leukocyte Antigen (HLA) genes—that makes them susceptible to a severe reaction when exposed to certain medications.

The Role of Genetics in SJS

The risk of developing Stevens-Johnson Syndrome is linked to specific HLA alleles, which help the immune system distinguish the body’s own proteins from foreign invaders. For example, the presence of the HLA-B*15:02 allele is a known risk factor for SJS when taking certain anti-seizure medications in specific populations. However, inheriting this gene does not guarantee that a person will develop Stevens-Johnson Syndrome; it simply increases the likelihood of a reaction occurring if the drug is administered.

Testing and Counseling

Because SJS is not a single-gene disorder, it does not follow Mendelian inheritance patterns, and there is no "risk percentage" for children of an affected parent. Genetic testing is not used to diagnose the condition itself, but it is increasingly used as a clinical tool before prescribing high-risk medications to prevent the onset of Stevens-Johnson Syndrome in susceptible individuals.

If you or a family member has experienced Stevens-Johnson Syndrome, genetic counseling can be incredibly helpful to discuss how these HLA markers might affect future medication choices for you and your relatives. Because these markers are inherited, your siblings or children might share the same susceptibility, making it vital to discuss your medical history with your healthcare provider before starting any new pharmacological treatments. De novo mutations are not a factor in the development of this condition, as it is a reaction to external triggers.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Stevens-Johnson Syndrome


• Orphanet: Epidermal necrolysis


• OMIM (Online Mendelian Inheritance in Man): HLA-B*15:02 and Drug-Induced Stevens-Johnson Syndrome